Business
Italfarmaco and JCR Pharmaceuticals Announce Commercialisation Agreement for Givinostat in Japan and Strategic Collaboration in Rare Disease
MILAN & HYOGO, Japan, December 24, 2025--JCR Pharmaceuticals and Italfarmaco announced an exclusive licensing agreement for the development and commercialization of givinostat in Japan.
About this update from Jcr Pharmaceuticals Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":251,"url":"https://media.zenfs.com/en/business-wire.com/1ebfe6d51c8ba41d746f5fcf82109ddf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gNdW_8MPDiOppFYht.b5bQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/1ebfe6d51c8ba41d746f5fcf82109ddf","width":480,"height":251}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":728,"height":265,"url":"https://media.zenfs.com/en/business-wire.com/20a151570d3b7152b6cdedc0c2df0dba"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MjkyBpd6RKZXuAPNef9Zzg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM0OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/20a151570d3b7152b6cdedc0c2df0dba","width":728,"height":265},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/euoDbnRygGczwysUAEPj5Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE0NTY7aD01MzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/20a151570d3b7152b6cdedc0c2df0dba","width":728,"height":265}}},{"type":"text","content":"- Italfarmaco grants JCR Pharmaceuticals exclusive rights to develop and commercialise givinostat in Japan -","length":108,"tagName":"p","attribs":{}},{"type":"text","content":"- Additional strategic collaboration in rare diseases aimed at enhancing both companies’ portfolios including exploring joint opportunities across JCR’s R&D pipeline and platform technologies -","length":197,"tagName":"p","attribs":{}},{"type":"text","content":"MILAN & HYOGO, Japan, December 24, 2025--(BUSINESS WIRE)--Italfarmaco S.p.A. and JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), today announced an exclusive licensing agreement for the development and commercialisation of givinostat in Japan.","length":258,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, JCR receives exclusive rights to commercialise givinostat for the treatment of Duchenne muscular dystrophy (DMD) in Japan and will be responsible for the local execution of clinical development activities, as well as regulatory submissions.","length":274,"tagName":"p"},{"type":"text","content":"Givinostat (marketed as Duvyzat® in the US, UK a...